Patents Assigned to Seraxis, Inc.
  • Macro-encapsulated therapeutic cells and methods of using the same
    Patent number: 11975031
    Abstract: Described are macro-capsules and barriers that can be used to prepare therapeutic cell implants, methods of encapsulating therapeutic cells, and methods of using the encapsulated cells in the treatment of disease.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: May 7, 2024
    Assignee: Seraxis, Inc.
    Inventor: William L. Rust
  • PANCREATIC CELLS FOR TREATING DIABETES AND METHODS OF GENERATING THE SAME
    Publication number: 20230031960
    Abstract: The present disclosure provides cell-based compositions for treating diabetes, methods for identifying cells that preferentially differentiate into endoderm cells, and methods for preparing insulin-producing pancreatic cells, as well as related methods of use for treating diseases related to insulin deficiency.
    Type: Application
    Filed: October 3, 2022
    Publication date: February 2, 2023
    Applicant: Seraxis, Inc.
    Inventor: William L. Rust
  • Pancreatic cells for treating diabetes and methods of generating the same
    Patent number: 11484554
    Abstract: The present disclosure provides cell-based compositions for treating diabetes, methods for identifying cells that preferentially differentiate into endoderm cells, and methods for preparing insulin-producing pancreatic cells, as well as related methods of use for treating diseases related to insulin deficiency.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: November 1, 2022
    Assignee: Seraxis, Inc.
    Inventor: William L. Rust
  • Macro-encapsulated therapeutic cells, devices, and methods of using the same
    Patent number: 11141508
    Abstract: Described are macro-capsules, barriers, and devices that can be used to prepare therapeutic cell implants, methods of encapsulating therapeutic cells, and methods of using the encapsulated cells in the treatment of disease.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: October 12, 2021
    Assignee: Seraxis, Inc.
    Inventor: William L Rust
  • PANCREATIC CELLS FOR TREATING DIABETES AND METHODS OF GENERATING THE SAME
    Publication number: 20210008122
    Abstract: The present disclosure provides cell-based compositions for treating diabetes, methods for identifying cells that preferentially differentiate into endoderm cells, and methods for preparing insulin-producing pancreatic cells, as well as related methods of use for treating diseases related to insulin deficiency.
    Type: Application
    Filed: February 8, 2019
    Publication date: January 14, 2021
    Applicant: Seraxis, Inc.
    Inventor: William L. Rust
  • MACRO-ENCAPSULATED THERAPEUTIC CELLS, DEVICES, AND METHODS OF USING THE SAME
    Publication number: 20190269832
    Abstract: Described are macro-capsules, barriers, and devices that can be used to prepare therapeutic cell implants, methods of encapsulating therapeutic cells, and methods of using the encapsulated cells in the treatment of disease.
    Type: Application
    Filed: February 28, 2019
    Publication date: September 5, 2019
    Applicant: Seraxis, Inc.
    Inventor: William L. Rust
  • MACRO-ENCAPSULATED THERAPEUTIC CELLS AND METHODS OF USING THE SAME
    Publication number: 20180289746
    Abstract: Described are macro-capsules and barriers that can be used to prepare therapeutic cell implants, methods of encapsulating therapeutic cells, and methods of using the encapsulated cells in the treatment of disease.
    Type: Application
    Filed: March 1, 2018
    Publication date: October 11, 2018
    Applicant: Seraxis, Inc.
    Inventor: William L. Rust
  • Stem cells and pancreatic cells useful for the treatment of insulin-dependent diabetes mellitus
    Patent number: 9968639
    Abstract: Fresh human pancreas tissue can be used as a source of cells when to identify and select a non-stem cell population that is predisposed to be a source for surrogate pancreatic cells that can be used in treating insulin-dependent diabetes. The progenitors of these surrogate pancreatic cells have no reprogramming genes integrated into their genomes, differentiate to the pancreatic lineage pursuant to a protocol that employs only defined reagents, and are substantially unable to differentiate to the mesodermal lineage.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: May 15, 2018
    Assignee: Seraxis, Inc.
    Inventor: William L. Rust
  • Method for generating non-pluripotent progenitors of surrogate pancreatic cells
    Patent number: 9474772
    Abstract: Fresh human pancreas tissue can be used as a source of cells whence to identify and select a non-stem cell population that is predisposed to be a source for surrogate pancreatic cells that can be used in treating insulin-dependent diabetes. The progenitors of these surrogate pancreatic cells have no reprogramming genes integrated into their genomes, differentiate to the pancreatic lineage pursuant to a protocol that employs only defined reagents, and are substantially unable to differentiate to the mesodermal lineage.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: October 25, 2016
    Assignee: Seraxis, Inc.
    Inventor: William L. Rust
  • STEM CELLS AND PANCREATIC CELLS USEFUL FOR THE TREATMENT OF INSULIN-DEPENDENT DIABETES MELLITUS
    Publication number: 20150231181
    Abstract: Fresh human pancreas tissue can be used as a source of cells whence to identify and select a non-stem cell population that is predisposed to be a source for surrogate pancreatic cells that can be used in treating insulin-dependent diabetes. The progenitors of these surrogate pancreatic cells have no reprogramming genes integrated into their genomes, differentiate to the pancreatic lineage pursuant to a protocol that employs only defined reagents, and are substantially unable to differentiate to the mesodermal lineage.
    Type: Application
    Filed: April 22, 2015
    Publication date: August 20, 2015
    Applicant: Seraxis, Inc.
    Inventor: William L. Rust